INVESTIGADORES
RUYBAL paula
artículos
Título:
Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40
Autor/es:
PAULA RUYBAL; MARÍA JOSÉ GRAVISACO; VIRNA BARCALA; ANA ESCALADA; PAULA DI SCIULLO; CLAUDIA WALDNER; CLAUDIA MONGINI
Revista:
VACCINE
Editorial:
Elsevier
Referencias:
Año: 2008 vol. 26 p. 697 - 705
ISSN:
0264-410X
Resumen:
The equal importance of the qualitative and quantitative characteristics of antigen
presentation as well as the set of costimulatory signals provided by antigen presenting
cells to T-cells in determining the outcome of T-cell responses at the time of antigen recognition
is now clear. Moreover, an important function in innate mechanisms has been recently
attributed to costimulatory molecules demonstrating their relevant role in different stages of
immune response. In this paper, we demonstrated the ability of CD40L (CD154) and CD80 costimulatory
molecules expression in a T-cell lymphoma to induce both T-cell dependent and
independent immune responses leading to an important anti-tumor effect. CD40 expression by
LBC cells enhanced only T-cell dependent anti-tumor immune response resulting in tumor rejection.
Furthermore, this work represents the first report to describe complete tumor rejection
after co-inoculation of lymphoma cells transfected with CD40L and CD80 in either presence or
absence of CD40 expressing lymphoma cells. In addition, this synergistic effect resulted in long
lasting immunity to parental tumor cells.
Co-inoculation of tumor cells each genetically modified to express a different costimulatory
molecule circumvents the need to co-transfect genetically unstable tumor cells and represents
an option for those weakly or non-immunogenic tumors where either treatment alone proved to
be inefficient. This strategy represents a promising approach for inducing anti-tumor immunity
and provides a new rational design of cancer therapies.